These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 31056

  • 1. Protection against experimental Proteus mirabilis pyelonephritis in rats and significance of immunity.
    Larsson P, Kaijser B, Olling S, Akerlund AS.
    Acta Pathol Microbiol Scand C; 1978 Oct; 86C(5):215-20. PubMed ID: 31056
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.
    Moayeri N, Collins CM, O'Hanley P.
    Infect Immun; 1991 Oct; 59(10):3778-86. PubMed ID: 1894376
    [Abstract] [Full Text] [Related]

  • 3. Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity.
    Kaijser B, Larsson P, Olling S.
    Infect Immun; 1978 Apr; 20(1):78-81. PubMed ID: 352939
    [Abstract] [Full Text] [Related]

  • 4. Immobilizing antibodies in urine. II. Prevention of ascending spread of Proteus mirabilis.
    Pazin GJ, Braude AI.
    Invest Urol; 1974 Sep; 12(2):129-33. PubMed ID: 4604561
    [No Abstract] [Full Text] [Related]

  • 5. [Proteus peritonitis-bacteremia in mice--a model for studying postvaccinal Proteus immunity].
    Zaĭtsev EV, Levina LA.
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jul; (7):74-8. PubMed ID: 2251896
    [Abstract] [Full Text] [Related]

  • 6. Urinary tract infections caused by Proteus mirabilis in children. The antibody response to O and H antigens and Tamm-Horsfall protein and bacterial adherence to uro-epithelium.
    Larsson P, Fasth A, Jodal U, Akerlund AS, Edén CS.
    Acta Paediatr Scand; 1978 Sep; 67(5):591-6. PubMed ID: 358736
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
    Pellegrino R, Galvalisi U, Scavone P, Sosa V, Zunino P.
    FEMS Immunol Med Microbiol; 2003 May 15; 36(1-2):103-10. PubMed ID: 12727373
    [Abstract] [Full Text] [Related]

  • 8. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P, Umpiérrez A, Rial A, Chabalgoity JA, Zunino P.
    Antonie Van Leeuwenhoek; 2014 Jun 15; 105(6):1139-48. PubMed ID: 24771125
    [Abstract] [Full Text] [Related]

  • 9. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HL.
    Infect Immun; 2004 Jan 15; 72(1):66-75. PubMed ID: 14688082
    [Abstract] [Full Text] [Related]

  • 10. [Specific immune preparations for the prevention and treatment of suppurative-inflammatory diseases of Proteus etiology (a review of the literature)].
    Nazarchuk LV.
    Lik Sprava; 1992 Jun 15; (6):28-34. PubMed ID: 1280887
    [Abstract] [Full Text] [Related]

  • 11. [Cell-mediated immunity in pyelonephritis: Passive transfer of adoptive immunity to retrograde Proteus mirabilis pyelonephritis in the rat (author's transl)].
    Araki T.
    Nihon Hinyokika Gakkai Zasshi; 1977 Aug 15; 68(8):771-9. PubMed ID: 335141
    [No Abstract] [Full Text] [Related]

  • 12. THE ROLE OF IMMUNITY IN THE PATHOGENESIS OF EXPERIMENTAL RETROGRADE PYELONEPHRITIS.
    HUNTER BW, AKINS LL, SANFORD JP.
    J Exp Med; 1964 Jan 01; 119(6):869-79. PubMed ID: 14176291
    [Abstract] [Full Text] [Related]

  • 13. O antigens of Proteus mirabilis and Proteus vulgaris strains isolated from patients with bacteremia.
    Larsson P.
    J Clin Microbiol; 1980 Oct 01; 12(4):490-2. PubMed ID: 6999017
    [Abstract] [Full Text] [Related]

  • 14. [Protective properties of Proteus ribosomal vaccine].
    Ovetchin PV, Tsyganenko AIa.
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan 01; (1):19-23. PubMed ID: 6367317
    [Abstract] [Full Text] [Related]

  • 15. Rheumatoid arthritis and Proteus: a possible aetiological association.
    Ebringer A, Khalafpour S, Wilson C.
    Rheumatol Int; 1989 Jan 01; 9(3-5):223-8. PubMed ID: 2692130
    [Abstract] [Full Text] [Related]

  • 16. [Serological diagnosis and immunological aspects of Proteus infection. V. Design and trial of polyvalent antigenic preparations].
    Bidnenko SI, Mel'nitskaia EV, Rudenko AV, Nazarchuk LV.
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Feb 01; (2):49-53. PubMed ID: 3887814
    [Abstract] [Full Text] [Related]

  • 17. Cross-protection of mice provided by active and passive immunization against experimental infections with virulent Proteus rettgeri and Providencia bacteria.
    Penner JL, Whiteley GR.
    Infect Immun; 1978 May 01; 20(2):347-51. PubMed ID: 669801
    [Abstract] [Full Text] [Related]

  • 18. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
    Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, Zunino P.
    Microbes Infect; 2007 Jun 01; 9(7):821-8. PubMed ID: 17540603
    [Abstract] [Full Text] [Related]

  • 19. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
    Scavone P, Sosa V, Pellegrino R, Galvalisi U, Zunino P.
    Microbes Infect; 2004 Jul 01; 6(9):853-60. PubMed ID: 15374007
    [Abstract] [Full Text] [Related]

  • 20. Prevention of ascending pyelonephritis in mice by urease inhibitors.
    Aronson M, Medalia O, Griffel B.
    Nephron; 1974 Jul 01; 12(2):94-104. PubMed ID: 4600535
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.